a Infectious Diseases Clinic, and Departments of b Pneumology and c Pharmacology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Sir,
Studies in vitro and in animals have shown that killing of bacteria by ß-lactams is time dependent and maximal at relatively low concentrations, indicating optimal administration by continuous infusion. Continuous infusion of ceftazidime was recently reported to be well tolerated by children with cystic fibrosis.1 On the other hand, the bactericidal activity of aminoglycosides is concentration dependent in in vitro and animal models. Meta-analysis of efficacy in patients' administration indicates that single daily dosing of aminoglycosides is as effective as conventional dosing, with similar or lower toxicity. However, there is scant information about the safety of single daily dose of aminoglycosides given as repeat courses in cystic fibrosis patients. The aim of this study was to provide pharmacokinetic data in cystic fibrosis patients on administration of ceftazidime by continuous infusion and amikacin by single daily dosing.
Twelve patients [eight males, four females, mean age (range) 19 (1032) years, mean weight (range) 49 (2765) kg] admitted for treatment of acute pulmonary exacerbation of cystic fibrosis were included in the study, which was approved by the Ethics Committee of Erasme Hospital. Informed consent was obtained from each patient or their legal guardian. Two days before the sampling day, each patient was given ceftazidime 65 mg/kg (Glaxo Wellcome, Brussels, Belgium) iv over 30 min as a loading dose, followed by a continuous infusion of 200 mg/kg/day in 500 mL dextrose 5% administered via an infusion pump. Amikacin 30 mg/kg (Bristol-Myers Squibb, Brussels, Belgium) was administered iv over 30 min once daily. Antimicrobial therapy was continued for 14 days, and blood and sputum samples were taken on the third day of treatment. Timed serum (pre-dose, 30 min, 2, 4, 6, 8, 24 h post-dose) and bronchial (pre-dose, and 13, 35, 57, 79 and 2224 h intervals post-dose) secretion samples were collected after amikacin dosing. Sputum and separated serum were stored at 70°C within 1 h of sampling. Defrosted sputum was sonicated in a circulating water bath (4°C) (Sonicator W-225 R; Heat Systems-Ultrasonics, New York, NY, USA) (2 min, 100 W) and then centrifuged (12 000g, 3 min). Assays were performed on supernatant.
Amikacin was assayed using fluorescence polarization immunoassay (TDx; Abbott Diagnostics, Ottignies, Belgium) according to the manufacturer's recommendations. The manufacturer's published limit of detection for amikacin is 0.25 mg/L. Ceftazidime was assayed by HPLC. Calibrators and samples were prepared by mixing with an equal volume of 0.72% perchloric acid containing cefadroxil (0.5 mg/mL) as internal standard. This mixture was centrifuged at 1000g for 5 min. Aliquots of the supernatant were injected on to the column (Supelcosil LC-18-DB, 250 x 4.6 mm; Whatman, Maidstone, UK) with a mobile phase of 0.05 M ammonium dihydrogen orthophosphate containing 7% (v/v) acetonitrile pumped at a flow rate of 1.5 mL/min. The eluate was monitored at 257 nm. The limits of detection for ceftazidime were 0.20 and 0.25 mg/L for serum and sputum supernatant, respectively.
Amikacin pharmacokinetic parameters were calculated using a two compartment open model (Siphar 4.0; Simed, Créteuil, France). The area under the serum concentrationtime curve (AUC) was determined by the trapezoidal rule up to the last concentrations determined. Amikacin clearance was determined by multiplying the elimination rate constant by the distribution volume. Ceftazidime clearance was calculated by dividing the dose by the AUC. The values are reported as mean ± s.d. (range).
Concentrations of ceftazidime and amikacin in serum and sputum are presented in the Figure (a and b). The mean peak and trough values of amikacin in serum were 116 ± 37 (82192) mg/L and 0.3 ± 0.4 (<0.259.2) mg/L, respectively. The T1/2 ß was 2.6 ± 1.3 h, with a distribution volume of 20.0 ± 7.9 L (0.40 ± 0.16 L/kg), and a total clearance of 5.26 ± 1.42 L/h. The peak sputum concentration 2 h post-dose was 5.9 ± 2.7 (2.49) mg/L and the trough 1.4 ± 0.8 (<0.252.4) mg/L. The mean serum and sputum AUCs for amikacin were 235 ± 110 and 83.7 ± 43.4 mgh/L, respectively. The steady-state blood concentration of ceftazidime was 56.1 ± 23.3 mg/L (23.996) and the sputum concentration was 1.7 ± 2.2 (<0.210.5) mg/L. The mean serum and sputum AUCs for ceftazidime were 1387 ± 346 and 22.3 ± 18.3 mgh/L, respectively. The mean ratios AUCsputum:AUCserum for amikacin and ceftazidime were 25 ± 1.5% and 1.4 ± 1.4%, respectively. The overall clinical results were favourable and all the patients were discharged after 2 weeks of treatment without any adverse events (data not shown).
|
Acknowledgments
This work was supported by Glaxo Wellcome, Belgium and Bristol-Myers Squibb, Belgium.
Notes
* Correspondence address. Infectious Diseases Clinic, Erasme University Hospital, 808 Route de Lennik, B-1070 Brussels, Belgium. Tel: +32-2-5556746; Fax: +32-2-5553912; E-mail: baudouin.byl{at}ulb.ac.be
References
1 . Rappaz, I., Decosterd, L. A., Bille, J., Pilet, M., Belaz, N. & Roulet, M. (2000). Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. European Journal of Pediatrics 159, 91925.[ISI][Medline]
2 . Autret, E., Marchand, S., Breteau, M. & Grenier, B. (1986). Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. European Journal of Clinical Pharmacology 31, 7983.[ISI][Medline]
3 . Grenier, B., Autret, E., Marchand, S. & Thompson, R. (1987). Kinetic parameters of amikacin in cystic fibrosis children. Infection 15, 2959.[ISI][Medline]
4 . Langer, M., Cantoni, P., Bellosta, C. & Boccazzi, A. (1991). Penetration of ceftazidime into bronchial secretions in critically ill patients. Journal of Antimicrobial Chemotherapy 28, 92532.[Abstract]
5 . Giwercman, B., Meyer, C., Lambert, P. A., Reinert, C. & Hoiby, N. (1992). High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrobial Agents and Chemotherapy 36, 716.[Abstract]